LINC02112: A Long Intergenic Non-Protein Coding RNA (G285692)

Target Name: LINC02112

NCBI ID: G285692

LINC02112

Other Name(s): long intergenic non-protein coding RNA 2112 | Long intergenic non-protein coding RNA 2112

LINC02112: A Long Intergenic Non-Protein Coding RNA

Non-coding RNAs (ncRNAs) have emerged as a promising area of research in recent years due to their involvement in various cellular processes. These RNAs are not directly translated into proteins and include a wide range of functional categories, such as microRNAs, long non-coding RNAs (lncRNAs), and short non-coding RNAs (snRNAs). One of the defining features of lncRNAs is their ability to interact with other RNAs and proteins, providing a mechanism for the regulation of gene expression.

The LINC02112 gene is a non-coding RNA that has been identified in various organisms as a potential drug target and biomarker. It is a member of the LINC021 family of non-coding RNAs, which are characterized by their ability to interact with the protein encoded by the same gene. LINC02112 is unique due to its highly conserved sequence, length, and expression pattern.

The LINC02112 gene is located on chromosome 16 and has a length of approximately 2112 nucleotides. It is expressed in various tissues and cells of the organism, including the brain, heart, and liver. The expression pattern of LINC02112 is highly dynamic, with increased expression levels observed in the brain during development and aging.

LINC02112 has been shown to play a role in various cellular processes, including cell growth, apoptosis, and inflammation. It has been shown to regulate the expression of other genes, including the neurotransmitter transporter gene (SNAT), the stress response gene (STRN) candidate GFP-ASF, and the cell adhesion molecule E-cadherin.

In addition to its role in gene regulation, LINC02112 has also been shown to play a role in the development and progression of certain diseases. For example, LINC02112 has been shown to be downregulated in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This suggests that its levels may be a potential diagnostic or therapeutic target.

The potential drug target status of LINC02112 is supported by its expression in various disease models. For example, LINC02112 has been shown to be downregulated in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that targeting LINC02112 may be a potential strategy for cancer treatment.

In addition to its potential as a drug target, LINC02112 also has potential as a biomarker. Its highly conserved sequence and expression pattern make it a strong candidate for use as a diagnostic biomarker. For example, LINC02112 has been shown to be downregulated in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This suggests that its levels may be a potential indicator of disease status.

In conclusion, LINC02112 is a non-coding RNA that has been identified as a potential drug target and biomarker. Its unique expression pattern and conserved sequence make it a promising candidate for further research. Further studies are needed to determine the full scope of LINC02112's function in various cellular processes and its potential as a drug and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2112

The "LINC02112 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02112 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets